1 Recommendations

1 Recommendations

1.1 Crizotinib is recommended, within its marketing authorisation, as an option for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults. The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.

  • National Institute for Health and Care Excellence (NICE)